Amir F. Heshmatpour
Known title: CEO, PresidentCIK: 0001443035
Amir F. Heshmatpour's purchase track record
How the stock did after each of Amir F. Heshmatpour's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
5
of 9 since May 11, 2025
Stock higher 6 months later
20%
3 months: 14%
Median 6-month return
-18.8%
3 months: -17.5%
Beat the S&P 500
20%
median -32.6% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/11/2026 | NTHI | $310K | pending | pending | — |
| 8/14/2026 | NTHI | $108K | pending | pending | — |
| 5/1/2026 | NTHI | $42K | -14.0% | pending | — |
| 4/23/2026 | NTHI | $94K | -24.2% | pending | — |
| 4/10/2026 | NTHI | $49K | -17.5% | -48.9% | +14.6% |
| 4/2/2026 | NTHI | $235K | -25.7% | -48.6% | +16.5% |
| 11/21/2025 | NTHI | $185K | +69.8% | -8.9% | +13.2% |
| 5/23/2025 | NTHI | $15K | -19.4% | -18.8% | +13.8% |
| 5/11/2025 | NTHI | $107K | -16.5% | +65.7% | +16.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NTHI | ▲ Buy | Open Market | 35,000 | $115K | 9/15/2026 | View on chart |
| NTHI | ▲ Buy | Open Market | 15,000 | $59K | 9/14/2026 | View on chart |
| NTHI | ▲ Buy | Open Market | 37,000 | $136K | 9/11/2026 | View on chart |
| NTHI | ▲ Buy | Open Market | 9,000 | $50K | 8/18/2026 | View on chart |
| NTHI | ▲ Buy | Open Market | 3,000 | $13K | 8/17/2026 | View on chart |
| NTHI | ▲ Buy | Open Market | 12,000 | $45K | 8/14/2026 | View on chart |
| NTHI | ▲ Buy | Open Market | 10,000 | $42K | 5/1/2026 | View on chart |
| NTHI | ▲ Buy | Open Market | 10,000 | $45K | 4/28/2026 | View on chart |
| NTHI | ▲ Buy | Open Market | 10,000 | $49K | 4/23/2026 | View on chart |
| NTHI | ▲ Buy | Open Market | 10,000 | $49K | 4/10/2026 | View on chart |
| NTHI | ▲ Buy | Open Market | 5,000 | $26K | 4/9/2026 | View on chart |
| NTHI | ▲ Buy | Open Market | 10,000 | $56K | 4/8/2026 | View on chart |
| NTHI | ▲ Buy | Open Market | 5,000 | $32K | 4/6/2026 | View on chart |
| NTHI | ▲ Buy | Open Market | 20,000 | $122K | 4/2/2026 | View on chart |
| NTHI | ▲ Buy | Open Market | 6,000 | $39K | 11/24/2025 | View on chart |
| NTHI | ▲ Buy | Open Market | 20,000 | $120K | 11/21/2025 | View on chart |
| NTHI | ▲ Buy | Open Market | 4,000 | $26K | 11/21/2025 | View on chart |
| NTHI | ▲ Buy | Grant | 1,200,000 | — | 11/6/2025 | View on chart |
| NTHI | ▲ Buy | Open Market | 2,000 | $15K | 5/23/2025 | View on chart |
| NTHI | ▲ Buy | Open Market | 3,510 | $59K | 5/16/2025 | View on chart |
| NTHI | ▲ Buy | Open Market | 1,500 | $11K | 5/15/2025 | View on chart |
| NTHI | ▲ Buy | Open Market | 1,000 | $7K | 5/14/2025 | View on chart |
| NTHI | ▲ Buy | Open Market | 990 | $7K | 5/13/2025 | View on chart |
| NTHI | ▲ Buy | Open Market | 1,400 | $10K | 5/12/2025 | View on chart |
| NTHI | ▲ Buy | Open Market | 1,600 | $12K | 5/11/2025 | View on chart |
| NTHI | ▼ Sell | Other | 3,996 | $0 | 3/26/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
NeOnc Sets FDA Meeting for NEO212; Roth Starts Coverage
NeOnc Technologies has scheduled an in-person FDA End-of-Phase 1 meeting for November 17 regarding its NEO212 candidate. This regulatory milestone provides a clear next step for the company's development timeline. Additionally, Roth Capital initiated coverage with a price target of $20, which is at the top of the current analyst range.
NeOnc Sets FDA Meeting for NEO212; Roth Starts Coverage. NeOnc Technologies has scheduled an in-person FDA End-of-Phase 1 meeting for November 17 regarding its NEO212 candidate. This regulatory milestone provides a clear next step for the company's development timeline. Additionally, Roth Capital initiated coverage with a price target of $20, which is at the top of the current analyst range.